Jon Chambers

@drjonchambers1.bsky.social

Dorset Gas Man. Editor of the RCoA Bulletin. Co-chair of RCoA Training Committee. Elected RCoA Council. Member. All opinions my own…unless borrowed from others.

The latest issue of President's News is out now. Please check your inboxes for all the latest news from the College. This month's newsletter includes👇 🔹 Forthcoming 2025 Census 🔹 Response to NHSE announcement 🔹 Piloting new exam formats 🔹 CPOC opportunities

President's News. The newsletter for all fellows and members of the Royal College of Anaesthetists.
Picture of Dr Claire Shannon.

Doesn’t feel like 5 years already since we had to learn to don PPE, to work in it all day & make it last because there wasn’t enough of it. People have different opinions about what did & didn’t happen. I can only say that in 27 years of practice it was the worst thing I’ve ever seen, every day.

Bild

Please do join us on the 18/3 7-8pm. Focus will be on training and career progression. Keen to discuss things that are working well within the training programme and those things we can help improve. Also keen to focus on how we can better support career progression outside of training.

Royal College of Anaesthetists@rcoanews.bsky.social · 2y ago

Let's Talk! Join us for a lively and engaging discussion with Council members, College staff and each other! In March we’ll be joined by @drjonchambers1.bsky.social and our AiT Council reps. All members are welcome, especially AiTs. 18 March 2025 7.00-8.00pm Reserve a spot: ow.ly/b40w50UWGj3

Let's Talk (talk in a speech bubble)

Really important for patients to let their anaesthetist know if they’re taking a GLP-1 or dual GIP/GLP-1 receptor agonist. As anaesthetists, having this information early on enables us to provide an individualised assessment of the risks and deliver the safest anaesthetic.

Royal College of Anaesthetists@rcoanews.bsky.social · 2y ago

NEW: drug safety update on GLP-1 and dual GIP/GLP-1 receptor agonists and the risk of pulmonary aspiration during anaesthesia or deep sedation. The MHRA emphasises individualised risk assessment and asking patients directly about these medications: ow.ly/Rl1x50UQ5xu